Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$15.62 +0.8%	$14.52	$9.57 ▼ $30.41	$2.14B	0.96	1.54 million shs	1.20 million shs
BHC Bausch Health Cos	$6.19 +8.1%	$4.91	$3.96 ▼ $9.85	$2.12B	0.28	2.63 million shs	4.64 million shs
NAMS NewAmsterdam Pharma	$18.20 -1.6%	$18.39	$14.06 ▼ $27.29	$2.08B	-0.03	694,190 shs	633,421 shs
SAGE Sage Therapeutics	$9.13 +0.1%	$7.11	$4.62 ▼ $13.47	$571.10M	0.18	1.28 million shs	2.87 million shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	+0.77%	-6.69%	-0.76%	+3.38%	-33.74%
BHC Bausch Health Cos	+8.04%	+16.30%	+33.47%	-12.71%	-4.36%
NAMS NewAmsterdam Pharma	-1.57%	-11.22%	-4.36%	-24.39%	+6.37%
SAGE Sage Therapeutics	+0.11%	+34.86%	+29.14%	+13.98%	-15.07%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARWR Arrowhead Pharmaceuticals	3.6642 of 5 stars	3.4	1.0	3.4	2.8	2.5	0.0
BHC Bausch Health Cos	3.7797 of 5 stars	1.9	2.0	4.0	4.1	3.3	0.6
NAMS NewAmsterdam Pharma	3.0501 of 5 stars	3.5	2.0	0.0	2.5	5.0	0.0
SAGE Sage Therapeutics	3.0274 of 5 stars	2.0	1.0	4.0	2.9	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	2.75	Moderate Buy	$43.71	179.86% Upside
BHC Bausch Health Cos	1.86	Reduce	$7.42	19.76% Upside
NAMS NewAmsterdam Pharma	3.00	Buy	$42.89	135.65% Upside
SAGE Sage Therapeutics	2.00	Hold	$8.93	-2.15% Downside

Current Analyst Ratings Breakdown

Latest SAGE, NAMS, BHC, and ARWR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	NAMS NewAmsterdam Pharma	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$42.00
6/17/2025	SAGE Sage Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$9.00 ➝ $8.50
6/17/2025	SAGE Sage Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$8.00 ➝ $9.00
6/17/2025	SAGE Sage Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$12.00
6/17/2025	SAGE Sage Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$8.00 ➝ $8.50
6/16/2025	SAGE Sage Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
6/12/2025	NAMS NewAmsterdam Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00
6/10/2025	NAMS NewAmsterdam Pharma	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$44.00
6/4/2025	NAMS NewAmsterdam Pharma	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$42.00
5/20/2025	ARWR Arrowhead Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/13/2025	ARWR Arrowhead Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$21.00 ➝ $17.00

(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$3.55M	607.64	N/A	N/A	$1.54 per share	10.14
BHC Bausch Health Cos	$9.63B	0.24	$8.37 per share	0.74	($0.89) per share	-6.96
NAMS NewAmsterdam Pharma	$45.56M	44.85	N/A	N/A	$8.20 per share	2.22
SAGE Sage Therapeutics	$41.24M	13.86	N/A	N/A	$7.60 per share	1.20

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$599.49M	-$1.40	N/A	N/A	18.23	N/A	-45.33%	-12.49%	8/6/2025 (Estimated)
BHC Bausch Health Cos	-$46M	-$0.11	N/A	1.33	N/A	-0.41%	-540.45%	5.26%	7/30/2025 (Estimated)
NAMS NewAmsterdam Pharma	-$241.60M	-$1.88	N/A	N/A	N/A	-397.45%	-37.34%	-33.45%	8/6/2025 (Estimated)
SAGE Sage Therapeutics	-$400.67M	-$5.80	N/A	N/A	N/A	-747.63%	-68.99%	-60.67%	7/30/2025 (Estimated)

Latest SAGE, NAMS, BHC, and ARWR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q2 2025	ARWR Arrowhead Pharmaceuticals	-$0.06	$2.75	+$2.81	$2.75	$116.27 million	$542.71 million
5/8/2025	Q1 2025	NAMS NewAmsterdam Pharma	-$0.45	-$0.49	-$0.04	-$0.34	$1.46 million	$2.98 million
4/29/2025	Q1 2025	SAGE Sage Therapeutics	-$0.99	-$1.01	-$0.02	-$1.01	$14.12 million	$14.06 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BHC Bausch Health Cos	N/A	N/A	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	N/A	N/A	N/A	N/A	N/A
SAGE Sage Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	0.31	5.15	5.15
BHC Bausch Health Cos	N/A	1.35	0.97
NAMS NewAmsterdam Pharma	N/A	19.98	19.98
SAGE Sage Therapeutics	N/A	9.13	9.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
BHC Bausch Health Cos	78.65%
NAMS NewAmsterdam Pharma	89.89%
SAGE Sage Therapeutics	99.22%

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	4.30%
BHC Bausch Health Cos	8.05%
NAMS NewAmsterdam Pharma	20.84%
SAGE Sage Therapeutics	5.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	400	138.10 million	132.16 million	Optionable
BHC Bausch Health Cos	20,700	370.08 million	340.29 million	Optionable
NAMS NewAmsterdam Pharma	4	112.27 million	88.87 million	Optionable
SAGE Sage Therapeutics	690	62.62 million	59.18 million	Optionable

SAGE, NAMS, BHC, and ARWR Headlines

Recent News About These Companies

Sage Therapeutics (NASDAQ:SAGE) Rating Lowered to Hold at Piper Sandler

June 19 at 3:31 AM | americanbankingnews.com

Truist Financial Raises Sage Therapeutics (NASDAQ:SAGE) Price Target to $9.00

June 19 at 3:31 AM | americanbankingnews.com

Sage Therapeutics (NASDAQ:SAGE) Receives Neutral Rating from HC Wainwright

June 19 at 2:48 AM | americanbankingnews.com

SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE

June 18 at 11:03 PM | businesswire.com

Another Gene Therapy Death; Biopharma M&A Picks Up; a Vaccine Board of Vaccine Skeptics

June 18 at 7:01 PM | biospace.com

Sage Therapeutics (NASDAQ:SAGE) Price Target Raised to $8.50 at Canaccord Genuity Group

June 18 at 3:23 AM | americanbankingnews.com

SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal

June 17 at 3:41 PM | zacks.com

Sage Therapeutics (SAGE) Soars 35.4%: Is Further Upside Left in the Stock?

June 17 at 12:10 PM | zacks.com

Sage Therapeutics (NASDAQ:SAGE) Earns Neutral Rating from Piper Sandler

June 17 at 11:36 AM | marketbeat.com

Sage Therapeutics (NASDAQ:SAGE) Price Target Raised to $9.00

June 17 at 10:56 AM | marketbeat.com

HC Wainwright Reaffirms "Neutral" Rating for Sage Therapeutics (NASDAQ:SAGE)

June 17 at 10:37 AM | marketbeat.com

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Connect

June 17 at 10:00 AM | accessnewswire.com

Sage Therapeutics (NASDAQ:SAGE) Given New $8.50 Price Target at Canaccord Genuity Group

June 17 at 8:34 AM | marketbeat.com

After rebuffing Biogen, Sage pairs off with Supernus

June 17 at 12:27 AM | pharmaphorum.com

Supernus makes depression drug play with $795m Sage buyout

June 17 at 12:27 AM | msn.com

Sage, following Setbacks, to sell to Supernus for $561M

June 17 at 12:27 AM | biopharmadive.com

Supernus acquires struggling Sage for $561M, taking a flier on postpartum depression drug Zurzuvae

June 17 at 12:27 AM | fiercepharma.com

Sage’s Story Comes to ‘Good End’ With Up To $795M Acquisition by Supernus

June 17 at 12:27 AM | biospace.com

Sage Therapeutics gets acquired by Maryland drugmaker for up to $795 million

June 17 at 12:27 AM | bostonglobe.com

Sage Therapeutics Stock Soars 36% After Sale to Supernus Pharmaceuticals. What We Know.

June 17 at 12:27 AM | msn.com

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Sage Therapeutics, Inc.

June 16 at 5:31 PM | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SAGE, NAMS, BHC, and ARWR Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$15.62 +0.12 (+0.77%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$15.59 -0.03 (-0.20%)

As of 06/18/2025 07:09 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Bausch Health Cos NYSE:BHC

$6.19 +0.46 (+8.08%)

Closing price 06/18/2025 03:59 PM Eastern

Extended Trading

$6.26 +0.06 (+1.00%)

As of 06/18/2025 07:58 PM Eastern

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

NewAmsterdam Pharma NASDAQ:NAMS

$18.20 -0.29 (-1.57%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$18.46 +0.26 (+1.43%)

As of 06/18/2025 07:12 PM Eastern

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Sage Therapeutics NASDAQ:SAGE

$9.13 +0.01 (+0.11%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$9.18 +0.05 (+0.60%)

As of 06/18/2025 07:58 PM Eastern

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time